Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Acquires Rights to mRNA Cancer Therapy in $320 Million Deal

publication date: Jan 11, 2021

Beijing's BeiGene announced a $310 million agreement for China/Asia rights to an mRNA treatment developed by Strand Therapeutics for solid tumor cancers. Strand, a Cambridge, MA biotech, focuses on programmable mRNA therapies for cancer and other diseases. BeiGene made a $5 million upfront equity investment in Strand for an option to two Strand immuno-oncology programs using Strand’s intratumoral or systemic delivery mechanism, saying Strand's candidates are "cutting-edge novel programs." Strand also received an additional $10 million equity investment from an unnamed party. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.